With a budget of up to $20m, the collaboration will establish scalable, rapid manufacturing for recombinant-protein vaccines.

CEPI will work with Samsung Biologics to establish a scalable, rapid manufacturing process for recombinant-protein vaccines.

The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract ...

Focusing on the establishment of Sino Biological‘s Center for Bioprocessing (C4B) in Houston, it highlights how the ...

Tsukuba, Japan—Recombinant protein production for pharmaceuticals and other applications often involves infecting plants with bacteria carrying specific genes to accumulate desired proteins in plants.

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking ...

Non-specific Endonuclease Market to reach US$ 726.6 Bn by 2036 at 6.5% CAGR, driven by rising biotechnology research, ...

The pre-Series A funding round was co-led by existing backer WaterBridge Ventures and Japanese VC firm Enrission India Capital Founded in 2019, Loopworm manufactures high-protein animal feeds from ...